{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:57:47Z","timestamp":1793750267965,"version":"4.6.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Omalizumab has been approved for treating moderate-to-severe asthma in children aged over 6 years. Its application to asthmatic children with other allergic diseases has been rarely explored. The present study aims to explore the therapeutic efficacy of omalizumab in children with moderate-to-severe allergic asthma combined with chronic sinusitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The clinical data of children diagnosed with moderate-to-severe allergic asthma combined with chronic sinusitis and treated with omalizumab between September 2020 and April 2022 were retrospectively analyzed. Lung function indexes such as Childhood Asthma Control Test (C-ACT) scores, fractional exhaled nitric oxide (FeNO), and forced expiratory volume in the first second (FEV<jats:sub>1<\/jats:sub>) percent predicted (FEV<jats:sub>1<\/jats:sub>%pred), small airway function indexes, and the clinical symptoms of chronic sinusitis were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 26 children were observed for 16 weeks. After 16 weeks of omalizumab treatment, the significantly increased C-ACT scores (15.57\u2009\u00b1\u20093.25 points vs. 24.98\u2009\u00b1\u20095.21 points, <jats:italic>F<\/jats:italic>\u2009=\u200915.7112, <jats:italic>P\u2009<\/jats:italic>&amp;lt;\u20090.001) and decreased FeNO (31.55\u2009\u00b1\u200915.57\u2005ppb vs. 19.86\u2009\u00b1\u20099.80\u2005ppb, <jats:italic>F<\/jats:italic>\u2009=\u20094.4265, <jats:italic>P\u2009<\/jats:italic>=\u20090.0022), compared with those at baseline, were suggestive of well-controlled symptoms of asthma and improved lung function. FEV<jats:sub>1<\/jats:sub>%pred and FEV<jats:sub>1<\/jats:sub>\/forced vital capacity (FVC) ratio (the ratio of the forced expiratory volume in the first 1\u2005s to the forced vital capacity) increased after omalizumab treatment, although no significant differences were detected (<jats:italic>P\u2009<\/jats:italic>=\u20090.9954 and 0.9382, respectively). Peak expiratory flow (PEF) percent predicted (PEF%pred) and forced expiratory flow at 75% of FVC (FEF<jats:sub>75%<\/jats:sub>), 50% of FVC (FEF<jats:sub>50%<\/jats:sub>), and 25%\u201375% of FVC (FEF<jats:sub>25%\u201375%<\/jats:sub>) significantly increased after omalizumab treatment (<jats:italic>P\u2009<\/jats:italic>=\u20090.0477, &amp;lt;0.001, &amp;lt;0.001, and &amp;lt;0.001, respectively). Visual analog scale scores significantly decreased after omalizumab treatment (6.40\u2009\u00b1\u20092.98 points vs. 0.85\u2009\u00b1\u20090.40 points, <jats:italic>t<\/jats:italic>\u2009=\u200927.2419, <jats:italic>P\u2009<\/jats:italic>&amp;lt;\u20090.001), suggesting alleviation in the clinical symptoms of chronic sinusitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this study, it was found that omalizumab can effectively alleviate clinical symptoms and improve lung function and quality of life in children with moderate-to-severe allergic asthma combined with chronic sinusitis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/falgy.2023.1236798","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T05:27:22Z","timestamp":1697434042000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Therapeutic efficacy of omalizumab in children with moderate-to-severe allergic asthma combined with chronic sinusitis"],"prefix":"10.3389","volume":"4","author":[{"given":"Weikun","family":"Chong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3760\/cma.j.issn.0578-1310.2013.10.003","article-title":"Third nationwide survey of childhood asthma in urban areas of China","volume":"51","year":"2013","journal-title":"Chin J Pediatr"},{"key":"B2","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3760\/cma.j.issn.0578-1426.2019.09.004","article-title":"Chinese guidelines for the diagnosis and treatment of allergic asthma (2019, the first edition)","volume":"58","year":"2019","journal-title":"China J Intern Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jaip.2019.11.008","article-title":"Allergic endotypes and phenotypes of asthma","volume":"8","author":"Akar-Ghibril","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e26155","DOI":"10.1097\/MD.0000000000026155","article-title":"Effects of omalizumab in children with asthma: a protocol for systematic review and meta-analysis","volume":"100","author":"Chen","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.29262\/ram.v65i3.510","article-title":"Omalizumab in children with uncontrolled asthma: a real-life study carried out in Colombia","volume":"65","author":"Morales-M\u00fanera","year":"2018","journal-title":"Rev Alerg Mex"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1900598","DOI":"10.1183\/13993003.00598-2019","article-title":"The Global Initiative for Asthma (GINA): 25 years later","volume":"54","author":"Boulet","year":"2019","journal-title":"Eur Respir J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3760\/cma.j.issn.1673-0860.2013.03.001","article-title":"Suggestion of diagnosis and treatment for pediatric sinusitis","volume":"48","year":"2013","journal-title":"Clin J Otorhinolaryngol Head Neck Surg"},{"key":"B8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3760\/cma.j.issn.1673-0860.2019.02.001","article-title":"Chinese Guidelines for diagnosis and treatment of chronic rhinosinusitis (2018)","volume":"54","year":"2019","journal-title":"Clin J Otorhinolaryngol Head Neck Surg"},{"key":"B9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3109\/02770903.2016.1144199","article-title":"Uncontrolled asthma and its risk factors in Chinese children: a cross-sectional observational study","volume":"53","author":"Xiang","year":"2016","journal-title":"J Asthma"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.jaci.2017.03.002","article-title":"Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience","volume":"139","author":"Chipps","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/alr.22741","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis","volume":"11","author":"Orlandi","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.otc.2022.09.010","article-title":"Pediatric unified airway: chronic rhinosinusitis and lower-airway disease","volume":"56","author":"Mulinda","year":"2023","journal-title":"Otolaryngol Clin North Am"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17476348.2023.2168261","article-title":"Respiratory comorbidities in severe asthma: focus on the pediatric age","volume":"17","author":"Licari","year":"2023","journal-title":"Expert Rev Respir Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.jaip.2019.02.030","article-title":"IgE-mediated multimorbidities in allergic asthma and the potential for omalizumab therapy","volume":"7","author":"Humbert","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.rmed.2018.06.016","article-title":"Pediatric rhinosinusitis and asthma","volume":"141","author":"Poddighe","year":"2018","journal-title":"Respir Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.3390\/jcm12041485","article-title":"Current and emerging treatment options in sinus and nasal diseases: surgical challenges and therapeutic perspectives","volume":"12","author":"Zhao","year":"2023","journal-title":"J Clin Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3390\/jpm12060999","article-title":"Biologic therapies in pediatric asthma","volume":"12","author":"Perikleous","year":"2022","journal-title":"J Pers Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e26155","DOI":"10.1097\/MD.0000000000026155","article-title":"Effects of omalizumab in children with asthma","volume":"100","author":"Chen","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pharmthera.2018.05.015","article-title":"Approaches to target IgE antibodies in allergic diseases","volume":"191","author":"Balbino","year":"2018","journal-title":"Pharmacol Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jaci.2020.01.020","article-title":"Biologics for chronic rhinosinusitis with nasal polyps","volume":"145","author":"Bachert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7398","DOI":"10.3390\/jcm11247398","article-title":"Current and emerging treatment options in sinus and nasal diseases: a promising future in the appropriate therapies","volume":"11","author":"Lin","year":"2022","journal-title":"J Clin Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3760\/cma.j.cn115330-20201112-00864","article-title":"Three cases of refractory sinusitis with nasal polyps treated with anti IgE monoclonal antibody","volume":"56","author":"Sui","year":"2021","journal-title":"Clin J Otorhinolaryngol Head Neck Surg"},{"key":"B23","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/pai.12405","article-title":"Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents","volume":"26","author":"Rodrigo","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"E36","DOI":"10.1542\/peds.108.2.e36","article-title":"Treatment of childhood asthma with anti-immunoglobulin E antibody(omalizumab)","volume":"108","author":"Milgrom","year":"2001","journal-title":"Pediatrics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pulmoe.2018.01.005","article-title":"Severe asthma in obese patients: improvement of lung function after treatment with omalizumab","volume":"25","author":"Oliveira","year":"2019","journal-title":"Pulmonology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2174\/1573398X13666170426094536","article-title":"Omalizumab in children with severe allergic asthma: the Italian real-life experience","volume":"13","author":"Licari","year":"2017","journal-title":"Curr Respir Med Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.alit.2016.06.004","article-title":"Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma","volume":"66","author":"Odajima","year":"2017","journal-title":"Allergol Int"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2023.1236798\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T05:27:30Z","timestamp":1697434050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2023.1236798\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":27,"alternative-id":["10.3389\/falgy.2023.1236798"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2023.1236798","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"article-number":"1236798"}}